» Articles » PMID: 29045511

Mechanisms Regulating T-cell Infiltration and Activity in Solid Tumors

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2017 Oct 19
PMID 29045511
Citations 189
Authors
Affiliations
Soon will be listed here.
Abstract

T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tumor samples derived from long-surviving patients, and impressive clinical responses to various immunotherapies that reinvigorate them. Indeed, tumors can upregulate a wide array of defense mechanisms, both direct and indirect, to suppress the ability of Tcells to reach the tumor bed and mount curative responses upon infiltration. In addition, patient and tumor genetics, previous antigenic experience, and the microbiome, are all important factors in shaping the T-cell repertoire and sensitivity to immunotherapy. Here, we review the mechanisms that regulate T-cell homing, infiltration, and activity within the solid tumor bed. Finally, we summarize different immunotherapies and combinatorial treatment strategies that enable the immune system to overcome barriers for enhanced tumor control and improved patient outcome.

Citing Articles

Identifying perturbations that boost T-cell infiltration into tumours via counterfactual learning of their spatial proteomic profiles.

Wang Z, Farooq A, Chen Y, Bhargava A, Xu A, Thomson M Nat Biomed Eng. 2025; .

PMID: 40044819 DOI: 10.1038/s41551-025-01357-0.


Tumor-associated stroma shapes the spatial tumor immune microenvironment of primary Ewing sarcomas.

Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N bioRxiv. 2025; .

PMID: 39975230 PMC: 11838416. DOI: 10.1101/2025.01.31.635996.


CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors.

Sun Y, Yee E, Fujiwara Y, Dickinson K, Guo Y, Sun Z J Immunother Cancer. 2025; 13(1.

PMID: 39805660 PMC: 11749055. DOI: 10.1136/jitc-2024-010554.


Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.

Semilietof A, Stefanidis E, Gray-Gaillard E, Pujol J, DEsposito A, Reichenbach P J Immunother Cancer. 2025; 12(12.

PMID: 39794936 PMC: 11667476. DOI: 10.1136/jitc-2024-009504.


Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies.

Goncalves M, Warwas K, Meyer M, Schwartz-Albiez R, Bulbuc N, Zornig I Cancers (Basel). 2025; 16(24.

PMID: 39766150 PMC: 11674949. DOI: 10.3390/cancers16244251.